CAM comment deadline
This article was originally published in The Tan Sheet
Executive Summary
The comment period for FDA's draft guidance entitled "Complementary and Alternative Medicine Products and Their Regulation by the Food and Drug Administration" is currently still scheduled to end on April 30, a spokesperson for the agency said April 19. The American Herbal Products Association told FDA in an April 16 1letter the April 30 deadline in the Federal Register 2notice was incongruous with the 90-day comment period specified in the 3guidance. "It is AHPA's intent to file its comments on the draft guidance on or before May 29, 2007, the date set out in the draft guidance," AHPA General Counsel Tony Young (Kleinfeld, Kaplan & Becker) writes in the letter. "AHPA urges FDA to clarify this date error at the earliest opportunity, so that the general public will be timely informed of the correct date for filing of comments in this matter," he adds...
You may also be interested in...
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.